May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Infliximab in the Treatment of Chronic Non–infectious Ocular Inflammation
Author Affiliations & Notes
  • C.A. Samson
    Ophthalmology, New York Eye & Ear, New York, NY
    Medicine, New York Medical College, Valhalla, NY
  • K.M. Narayana
    Ophthalmology, New York Eye & Ear, New York, NY
  • P. Latkany
    Ophthalmology, New York Eye & Ear, New York, NY
  • S. Schwartzman
    Rheumatology, Hospital for Special Surgery, New York, NY
  • Footnotes
    Commercial Relationships  C.A. Samson, None; K.M. Narayana, None; P. Latkany, None; S. Schwartzman, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2837. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.A. Samson, K.M. Narayana, P. Latkany, S. Schwartzman; Infliximab in the Treatment of Chronic Non–infectious Ocular Inflammation . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2837.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the efficacy and safety of infliximab in the treatment of chronic non–infectious ocular inflammation Methods: Charts of patients with chronic non–infectious ocular inflammation treated with infliximab were reviewed retrospectively Results: Five patients with uveitis and two patients with scleritis treated with infliximab were seen between 2000 and 2004. The mean patient age was 42 years (range: 12–70). Five patients were female. The mean follow–up time was 21.5 months. Ocular inflammation was controlled in five patients. Reduction of oral presdnisone was possible in 3 patients. No adverse reactions related to infliximab occurred in the follow–up period. Conclusions: Infliximab can be an effective treatment for non–infectious inflammation, and can allow reduction in the required steroid dose. There were no serious side–effects in this pilot retrospective case series.

Keywords: immunomodulation/immunoregulation • uveitis-clinical/animal model • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×